OXP001

OXP001 is a novel formulation of ibuprofen developed by Oxford Pharmascience using its proprietary OXPzero technology platform. It delivers 400 mg of ibuprofen as a novel salt designed to significantly reduce the risk of gastrointestinal side effects, such as irritation and damage, which are commonly associated with the chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs). By masking the acidic group of the ibuprofen molecule, the OXPzero technology aims to provide a safer profile while maintaining the efficacy of standard ibuprofen for treating pain and inflammation, including musculoskeletal conditions. The formulation is designed to be bioequivalent to standard ibuprofen while demonstrating reduced gastroduodenal irritation in clinical assessments.

Brand names

OXProfen

Other names

OXPzero Ibuprofen